Table summarizing the best characterized CXCR1/2 small molecule antagonists available from a range of pharmaceutical companies, and the pre-clinical cancer studies and clinical trials in other inflammatory conditions in which they have be utilized. The gene discussed is CXCR1; the disease is cancer.